Pekka Kurki

Company: Finnish Medicines Agency
Pekka

Dr. Pekka Kurki, M.D, Ph.D, acts as a research professor at the Finnish Medicines Agency (Fimea).

Before joining the Finnish regulatory agency in 1997, he worked in the pharmaceutical industry (clinical research), both in Europe and in the U.S.A. Dr. Kurki's clinical speciality is internal medicine with sub-speciality in rheumatology. He has a teaching affiliation to the University of Helsinki (clinical immunology). His scientific interest also includes cell biology, rheumatology and regulatory science.

He has had several scientific positions at the European Medicines Agency (EMA), including the membership the Committee of Human Medicinal Products (CHMP, 2000-7), chairmanships of the working parties for comparability (2002-3), biosimilars (BMWP, 2004-7), cell therapy (2002-4), and cell-based medicinal products (CPWP 2005-7). In addition, he acted as the chair of the ad hoc group for xenogeneic cell therapy (2001-3), a member of the biologicals working party (BWP, 1998-9) and a member of the ad hoc innovation Think Tank group of EMA (2005-7).

Currently, he is an alternate member of the EMA management board and an expert in the BMWP.